In an analysis of investigating relationships among T2D treatment and AD biomarkers, McIntosh and others found that T2D treatment was related to lower CSF levels of p-tau, t-tau, and p-tau/Aβ1-42 when compared to untreated persons with T2D (McIntosh and Nation, 2019). This evidence concerns the gene MAPT and Alzheimer disease.